Truist lowered the firm’s price target on Glaukos (GKOS) to $120 from $126 but keeps a Buy rating on the shares. Positioning in the stock in recent weeks has been potentially begun to turn a bit more positive with a view that an accelerating iDose trajectory into 2026 could begin to take form as reimbursement bottlenecks continue to ease in the wake of more MACs establishing physician fees, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Stifel sees opportunity in Glaukos selloff, adds to Select List
- Glaukos Receives Buy Rating from Analyst Ryan Zimmerman Due to Strong Growth and Promising Product Potential
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Glaukos Highlights Innovation in Recent Investor Presentation
- Glaukos Corp. Reports Record Growth Amid Challenges